跳转至内容
Merck
CN

K3502

抗 人 κ 轻链(结合和游离) 山羊抗

affinity isolated antibody, lyophilized powder

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.46
MDL number:
Conjugate:
unconjugated
Clone:
polyclonal
Application:
quantitative precipitin assay
Technique(s):
quantitative precipitin assay: suitable
Citations:
15
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

抗 人 κ 轻链(结合和游离) 山羊抗, affinity isolated antibody, lyophilized powder

biological source

goat

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

secondary antibodies

clone

polyclonal

form

lyophilized powder

technique(s)

quantitative precipitin assay: suitable

storage temp.

2-8°C

target post-translational modification

unmodified

Quality Level

Gene Information

human ... IGK@(50802)

正在寻找类似产品? 访问 产品对比指南

Application

基于玉米种子提取物进行ELISA 时(工作抗体稀释度1:200),抗人κ轻链(结合和游离)-FITC 抗体用作二抗。使用NSO/1骨髓瘤细胞、HEK293细胞和小鼠血浆进行ELISA时,使用1-2 μg/ml的抗体浓度。制备抗莠去津免疫传感器时,该抗体还用于包被电极表面。
山羊抗人κ轻链(结合和游离态)抗体可用于蛋白质免疫印迹。

Disclaimer

除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

General description

抗人 κ轻链(结合和游离)抗体获自山羊抗血清。免疫特异性纯化去除所有不与 κ轻链(结合和游离)。抗体制备对 κ对照结合和游离轻链检测时的轻链。产物不与结合或游离 λ 反应轻链。

Immunogen

纯化的人正常和骨髓瘤 κ轻链

Physical form

从 0.01 M 磷酸钠、0.015 M 氯化钠 (pH 7.2) 冻干

Preparation Note

用 0.135 M 氯化钠复溶。

未找到合适的产品?  

试试我们的产品选型工具.

法规信息

常规特殊物品
常规特殊物品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Characterization of immunological interactions at an immunoelectrode by scanning electron microscopy
Ambrosi A et al
Electroanalysis, 19, 244-252 (2007)
Eva Gschmack et al.
Journal of neural transmission (Vienna, Austria : 1996), 129(5-6), 545-555 (2022-04-03)
Idiopathic Parkinson's disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus-subcoeruleus complex; (stage 2)
Yvonne J Rosenberg et al.
PloS one, 11(3), e0152760-e0152760 (2016-04-01)
Intravascular delivery of broadly neutralizing antibodies (bnAbs) has shown promise for prevention and treatment of HIV infection. However, multiple IV administrations in geographic locations with poor accessibility to medical care have practical limitations. We have assessed the efficacy of plant-derived
Koreen Ramessar et al.
Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3727-3732 (2008-03-05)
A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite
Sven Mathias et al.
Biotechnology and bioengineering, 117(1), 5-16 (2019-10-22)
Although most therapeutic monoclonal antibodies (mAbs) can routinely be produced in the multigram per litre range, some mAb candidates turn out to be difficult-to-express (DTE). In addition, the class of more complex biological formats is permanently increasing and mammalian expression

相关内容

Instructions

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持